Table 2.
Distribution of genotype and allele frequencies of TP53 codon 72 and 16-bp duplication polymorphisms in breast cancer cases and controls
| Polymorphism | Genotype | BC cases | Controls | Padj valuea | ORaadj (95% CI) | Armitage’s trend test |
|---|---|---|---|---|---|---|
| Codon 72 | Additive model | |||||
| Arg/Arg | 66 (26.0%) | 82 (32.5%) | Reference |
Ptrend = 0.58 OR trend = 1.05 |
||
| Arg/Pro | 149 (58.7%) | 123 (48.8%) | 0.10 | 1.43 (0.93–2.18) | ||
| Pro/Pro | 39 (15.3%) | 47 (18.7%) | 0.72 | 1.11 (0.63–1.95) | ||
| Dominant model | ||||||
| Arg/Arg | 66 (26.0%) | 82 (32.5%) | Reference | |||
| Arg/Pro + Pro/Pro | 188 (74.0%) | 170 (67.5%) | 0.16 | 1.34 (0.89–2.02) | ||
| Recessive model | ||||||
| Arg/Arg + Arg/Pro | 215 (84.7%) | 205 (81.3%) | Reference | |||
| Pro/Pro | 39 (15.3%) | 47 (18.7%) | 0.62 | 0.88 (0.54–1.44) | ||
| Allele | Arg | 281 (55.3%) | 287 (56.9%) | Reference | ||
| Pro | 227 (44.7%) | 217 (43.1%) | 0.52 | 1.09 (0.84–1.42) | ||
| 16-bp duplication | Additive model |
Ptrend = 0.86 OR trend = 0.95 |
||||
| Del/Del | 230 (90.6%) | 227 (90.1%) | Reference | |||
| Del/Ins | 24 (9.4%) | 25 (9.9%) | 0.58 | 0.84 (0.44–1.58) | ||
| Ins/Ins | 0 (–) | 0 (–) | – | – | ||
| Dominant model | ||||||
| Del/Del | 230 (90.6%) | 227 (90.1%) | Reference | |||
| Del/Ins + Ins/Ins | 24 (9.4%) | 25 (9.9%) | 0.58 | 0.84 (0.44–1.58) | ||
| Recessive model | ||||||
| Del/Del + Del/Ins | 254 (100%) | 252 (100%) | Reference | |||
| Ins/Ins | 0 (–) | 0 (–) | – | – | ||
| Allele | Del | 484 (95.3%) | 479 (95.0%) | Reference | ||
| Ins | 24 (4.7%) | 25 (5.0%) | 0.59 | 0.84 (0.45–1.57) | ||
BC cases breast cancer cases, OR odds ratio, CI confidence interval
aAdjusted by age